Inhibikase Therapeutics, Inc. announced on February 24, 2025, the appointment of two pharma industry executives with deep experience in pulmonary arterial hypertension (PAH) to its senior leadership team. Chris Cabell, M.D., was appointed President and Head of Research & Development.
John Adams, Ph.D., co-founder of CorHepta and former Head of Research at Arena Pharmaceuticals, was appointed Chief Scientific Officer. These appointments are expected to accelerate the build-out of the team as the company prepares to execute on the IkT-001 Phase 2 clinical trial in PAH.
Additionally, Vince Aurentz, with extensive experience in corporate strategy and business development, will join the Inhibikase Board of Directors. These additions aim to strengthen the company's expertise and operational capabilities for its lead PAH program.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.